Navigation

Costing tools

Costing tools are normally provided for each technology appraisal, quality standard, medical technology, diagnostic technology, clinical guideline and public health guidance. Costing tools are not provided for interventional procedures.

Types of costing tool

NICE provides five types of costing tool:

  • national cost reports summarise the national estimate cost and discuss the assumptions made when estimating the financial impact of implementing the guidance. For technology appraisals, the report is incorporated into the costing template.
  • costing templates support estimating the local cost of implementing guidance. and public health guidelines. These templates allow individual NHS organisations and local health economies to quickly assess the impact guidance will have on local budgets. A video tutorial explaining how to use the costing templates is available in Windows Media Player and Quick Time format.
  • business case. It presents the financial costs and benefits of implementing guidance.
  • cost impact and commissioning assessment for NICE quality standards
  • costing statements are used when cost impact is considered to be minimal to explain why the cost impact is not considered to be significant.
  • NICE support for commissioners and others using the quality standard

All guidance published since January 2005 has costing tools. Costing tools currently available are listed below.

Further information on the methodology for developing costing tools.

Results 1-20 of 515

Ref Title
TA99 Renal transplantation - immunosuppressive regimens for children and adolescents: costing statement
TA95 Arrhythmia - implantable cardioverter defibrillators (ICDs) (review): analysis of cost impact
TA311 Multiple myeloma - bortezomib (induction therapy): costing statement
TA310 Lung cancer (non small cell, EGFR mutation positive) - afatinib: costing statement
TA309 Lung cancer (non small cell, non squamous) - pemetrexed: costing statment
TA308 Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids): costing statement
TA307 Colorectal cancer (metastatic) - aflibercept: costing statement
TA306 Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: costing statement
TA305 Macular oedema (central retinal vein occlusion) - aflibercept solution for injection: costing template
TA304 Arthritis of the hip (end stage) - hip replacement (total) and resurfacing arthroplasty (Rev TA2, TA44): costing statement
TA303 Multiple sclerosis (relapsing) - teriflunomide: costing template
TA301 Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271): costing template
TA300 Hepatitis C (children and young people) - peginterferon alfa and ribavirin: costing statement
TA299 Leukaemia (chronic myeloid) - bosutinib: costing statement
TA298 Choroidal neovascularisation (pathological myopia) - ranibizumab: costing statement
TA297 Vitreomacular traction - ocriplasmin: costing template
TA296 Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib: costing statement
TA295 Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor): costing statement
TA294 Macular degeneration (wet age-related) - aflibercept: costing template
TA293 Thrombocytopenic purpura - eltrombopag: costing statement

This page was last updated: 31 August 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.